Euroopa Liit - eesti - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant võib kasutada monoteraapiana või kombinatsioonis metotreksaadiga. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.

Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig  - abrocitinib - dermatiit, atoopiline - muud dermatoloogilised preparaadid - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.

Euroopa Liit - eesti - EMA (European Medicines Agency)

ab science s.a. - masitinib mesilate - antineoplastilised ained - koerad - ravi mitte-resectable koer mast-rakkude kasvajad (klass 2 või 3), kellel on kinnitatud muteerunud c-kit türosiin-kinase retseptori.

Euroopa Liit - eesti - EMA (European Medicines Agency)

ab science - masitinib mesilate - amüotroofiline lateraalskleroos - antineoplastilised ained - ravi lateraalskleroosi.

Euroopa Liit - eesti - EMA (European Medicines Agency)

ab science - masitinib mesilate - mastotsütoos - antineoplastilised ained - ravi mastocytosis.

Euroopa Liit - eesti - EMA (European Medicines Agency)

angelini pharma s.p.a - cenobamate - epilepsia - antiepileptics, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.

Euroopa Liit - eesti - EMA (European Medicines Agency)

ab science - masitiniib - pankrease neoplasmid - protein kinase inhibiitorid - ravi mitte resectable lokaalselt kaugelearenenud või metastaatiline pankrease vähk.

Euroopa Liit - eesti - EMA (European Medicines Agency)

masitiniib - seedetraktist esinevad stromaal-kasvajad - protein kinase inhibiitorid - ravi unresectable ja/või metastaatilise pahaloomulise seedetrakti stromal kasvaja (pÕhilised).